| Catalog No. | HW342026 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | ACT35 antigen, TXGP1L, TAX transcriptionally-activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TNFRSF4, OX40L receptor, CD134 |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P43489 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | Vonlerolizumab,MOXR-0916,MOXR0916,RG-7888,RO7021608,CAS:1638935-72-4 |
|---|
| Background | Pogalizumab, also known as MOXR0916 or vonlerolizumab, is a humanized IgG monoclonal antibody that targets OX40 (CD134), a co-stimulatory receptor belonging to the tumor necrosis factor receptor superfamily (TNFRSF). OX40 is predominantly expressed on activated T cells and plays a crucial role in enhancing T-cell proliferation, survival, and cytokine production. By agonistically binding to OX40, pogalizumab aims to potentiate anti-tumor immune responses by promoting effector T-cell activity and inhibiting regulatory T-cell (Treg) functions. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
